Medtronic Lowers Full-Year Earnings Outlook Amid MiniMed IPO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MDT?
Source: seekingalpha
- Earnings Outlook Downgrade: Medtronic (MDT) has lowered its non-GAAP earnings per share forecast for fiscal 2026 to $5.50 - $5.54 from a previous range of $5.62 - $5.66 due to the recent IPO of its diabetes business MiniMed Group (MMED), indicating significant pressure on profitability.
- IPO Impact Analysis: The public listing of MiniMed (MMED) on March 9 is expected to create a $0.04 per share dilutive effect for Medtronic (MDT), highlighting the direct financial implications of the new listing and potentially undermining investor confidence.
- One-Time Expense Burden: MiniMed (MMED) will incur a one-time charge of $157 million due to payments owed to Blackstone (BX), which will impact earnings by $0.08 per share in Q4 FY26, further exacerbating the company's financial challenges.
- Future Growth Outlook: Despite the current earnings downgrade, Medtronic (MDT) maintains its outlook for high single-digit EPS growth for fiscal 2027, reflecting confidence in the company's long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 87.170
Low
102.00
Averages
111.76
High
120.00
Current: 87.170
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Receives FDA Approval for New Defibrillation Lead
- FDA Approval for New Indication: Medtronic's OmniaSecure™ defibrillation lead has received FDA approval for placement in the left bundle branch area, supporting conduction system pacing and enhancing patient outcomes, marking a significant innovation in cardiac medical technology.
- Market Leadership: As the smallest diameter defibrillation lead on the market (4.7 French), the OmniaSecure™ is suitable for both adults and pediatric patients aged 12 and up, further broadening Medtronic's customer base and enhancing its competitive edge.
- Clinical Trial Support: Data from the global LEADR LBBAP trial shows a 100% defibrillation success rate at implant and a low major complication rate of 2.1% at three months, providing strong clinical evidence for its safety and effectiveness.
- Product Portfolio Expansion: This approval enriches Medtronic's portfolio of lumenless leads and accessories, strengthening its market position in conduction system pacing and is expected to drive future sales growth and technology applications.
See More
Medtronic Lowers Full-Year Earnings Outlook Amid MiniMed IPO
- Earnings Outlook Downgrade: Medtronic (MDT) has lowered its non-GAAP earnings per share forecast for fiscal 2026 to $5.50 - $5.54 from a previous range of $5.62 - $5.66 due to the recent IPO of its diabetes business MiniMed Group (MMED), indicating significant pressure on profitability.
- IPO Impact Analysis: The public listing of MiniMed (MMED) on March 9 is expected to create a $0.04 per share dilutive effect for Medtronic (MDT), highlighting the direct financial implications of the new listing and potentially undermining investor confidence.
- One-Time Expense Burden: MiniMed (MMED) will incur a one-time charge of $157 million due to payments owed to Blackstone (BX), which will impact earnings by $0.08 per share in Q4 FY26, further exacerbating the company's financial challenges.
- Future Growth Outlook: Despite the current earnings downgrade, Medtronic (MDT) maintains its outlook for high single-digit EPS growth for fiscal 2027, reflecting confidence in the company's long-term growth potential.
See More
HMH Holding IPO: Enery to Launch Public Offering Amid Rising Oil Prices
- Impact of Crude Prices: Oil drillers and energy stocks have seen significant gains this year due to rising crude prices.
- Geopolitical Factors: The surge in crude prices is attributed to the ongoing war in Iran and concerns over supply constraints.
See More
Medtronic PLC Updates FY2026 Non-GAAP EPS Forecast to $5.50-$5.54 in SEC Filing
- Revised Guidance: Medtronic PLC has updated its fiscal year 2026 non-GAAP earnings per share guidance.
- Earnings Range: The new guidance estimates earnings per share to be between $5.50 and $5.54.
See More
Medtronic Enters Exclusive Agreement with Merit for BVNA System
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
See More
Medtronic and Merit Medical Systems Partner to Launch FDA-Cleared ViaVerte™ System for Chronic Lower Back Pain Treatment
Agreement Announcement: Medtronic has entered into an agreement to offer a new treatment for chronic vertebrogenic lower back pain.
FDA Clearance: The treatment involves the use of the FDA-cleared VERTEX™ system, which is designed for ablation of nerve tissue.
See More
Medtronic Receives FDA Approval for New Defibrillation Lead
- FDA Approval for New Indication: Medtronic's OmniaSecure™ defibrillation lead has received FDA approval for placement in the left bundle branch area, supporting conduction system pacing and enhancing patient outcomes, marking a significant innovation in cardiac medical technology.
- Market Leadership: As the smallest diameter defibrillation lead on the market (4.7 French), the OmniaSecure™ is suitable for both adults and pediatric patients aged 12 and up, further broadening Medtronic's customer base and enhancing its competitive edge.
- Clinical Trial Support: Data from the global LEADR LBBAP trial shows a 100% defibrillation success rate at implant and a low major complication rate of 2.1% at three months, providing strong clinical evidence for its safety and effectiveness.
- Product Portfolio Expansion: This approval enriches Medtronic's portfolio of lumenless leads and accessories, strengthening its market position in conduction system pacing and is expected to drive future sales growth and technology applications.
See More
Medtronic Lowers Full-Year Earnings Outlook Amid MiniMed IPO
- Earnings Outlook Downgrade: Medtronic (MDT) has lowered its non-GAAP earnings per share forecast for fiscal 2026 to $5.50 - $5.54 from a previous range of $5.62 - $5.66 due to the recent IPO of its diabetes business MiniMed Group (MMED), indicating significant pressure on profitability.
- IPO Impact Analysis: The public listing of MiniMed (MMED) on March 9 is expected to create a $0.04 per share dilutive effect for Medtronic (MDT), highlighting the direct financial implications of the new listing and potentially undermining investor confidence.
- One-Time Expense Burden: MiniMed (MMED) will incur a one-time charge of $157 million due to payments owed to Blackstone (BX), which will impact earnings by $0.08 per share in Q4 FY26, further exacerbating the company's financial challenges.
- Future Growth Outlook: Despite the current earnings downgrade, Medtronic (MDT) maintains its outlook for high single-digit EPS growth for fiscal 2027, reflecting confidence in the company's long-term growth potential.
See More
HMH Holding IPO: Enery to Launch Public Offering Amid Rising Oil Prices
- Impact of Crude Prices: Oil drillers and energy stocks have seen significant gains this year due to rising crude prices.
- Geopolitical Factors: The surge in crude prices is attributed to the ongoing war in Iran and concerns over supply constraints.
See More
Medtronic PLC Updates FY2026 Non-GAAP EPS Forecast to $5.50-$5.54 in SEC Filing
- Revised Guidance: Medtronic PLC has updated its fiscal year 2026 non-GAAP earnings per share guidance.
- Earnings Range: The new guidance estimates earnings per share to be between $5.50 and $5.54.
See More
Medtronic Enters Exclusive Agreement with Merit for BVNA System
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
See More
Medtronic and Merit Medical Systems Partner to Launch FDA-Cleared ViaVerte™ System for Chronic Lower Back Pain Treatment
Agreement Announcement: Medtronic has entered into an agreement to offer a new treatment for chronic vertebrogenic lower back pain.
FDA Clearance: The treatment involves the use of the FDA-cleared VERTEX™ system, which is designed for ablation of nerve tissue.
See More
